IP Library Granted Patent US 10,729,741
Granted Patent B2
US 10,729,741 · App. 15/469,988 · Granted Aug 4, 2020

Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury

Inventors: Richard August Clark (Setauket, NY); Fubao Lin (Stony Brook, NY)
Assignee: NeoMatrix Therapeutics Inc.
A61K38/12A61K9/0019A61K38/39
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,729,741
App. No.
15/469,988
Granted
Aug 4, 2020
Kind
B2
Abstract

A treatment window for the intravenous treatment of wounds, including thermal and chemical burns, with cP12 is presented. In particular, Applicants have unexpectedly found that delaying intravenous treatment with fibronectin-derived peptides, such as cP12, from 2 to 6 hours, particularly about 4 hours, after wounding, provides superior wound-closing results than treatment at 1 hour or after 8 or more hours.

Claims (9)

1. A method of treating a patient with a wound selected from the group consisting of a surgical incision or extirpation, a traumatic injury, a thermal burn, a chemical burn, a lesion or ulceration of the patient's skin, mucosa, connective tissue, fascia, ligament, tendon, cartilage, nerve, or muscle, and a wound to the patient's bone, the method comprising:

intravenously administering to the patient a therapeutically effective amount of a cyclized form of a polypeptide consisting of amino acids PSHISKYILRWRPK (SEQ ID NO:2), wherein the dosage is from 0.003 to 0.1 mg/kg and wherein the intravenous administration occurs from about 2 hours to about 6 hours after formation of the wound.

2. The method of claim 1 , wherein the wound is a thermal burn or a chemical burn.

3. The method of claim 2 , wherein the wound is a thermal burn.

4. The method of claim 2 , wherein the intravenous administration is initiated about 4 hours after formation of the wound and the intravenous administration is given over about a half-hour period.

5. The method of claim 4 , wherein the dosage is from 0.03 to 0.1 mg/kg.

6. The method of claim 3 , wherein the intravenous administration is initiated about 4 hours after formation of the wound and the intravenous administration is given over about a half-hour period.

7. The method of claim 6 , wherein the dosage is from 0.03 to 0.1 mg/kg.

8. The method of claim 1 , wherein the polypeptide is cyclized by chemical crosslinking, chemical intramolecular ligation or enzymatic intramolecular ligation.

Assignments (3)
CONFIRMATORY LICENSE Recorded Mar 17, 2026
From: NEOMATRIX THERAPEUTICS, INC
To: UNITED STATES GOVERNMENT
Reel/Frame 075170/0900 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2020
From: CLARK, RICHARD AUGUST, DR.; LIN, FUBAO, DR.
To: NEOMATRIX FORMULATIONS, INC.
Reel/Frame 051930/0286 →
CHANGE OF NAME Recorded Feb 13, 2020
From: NEOMATRIX FORMULATIONS, INC.
To: NEOMATRIX THERAPEUTICS INC.
Reel/Frame 051930/0355 →
Continuity (1)
Related Publication 20180271934A1 · Sep 27, 2018